m+Medelevator.RU
← Поиск публикаций
Frontiers in medicine · 2025

Fire needling therapy for neurodermatitis: a systematic review and meta-analysis of randomized controlled trials.

СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Qiu Xiao, Hu Xiangyu, Jia Ruiling, Ding Yuting, Wang Yuyi

Аннотация

OBJECTIVE: This meta-analysis aimed to evaluate the clinical effectiveness and safety of fire needling therapy for neurodermatitis, either as monotherapy or in combination with conventional treatments.

METHODS: Following PRISMA 2020 guidelines, randomized controlled trials were systematically searched across Chinese and English databases up to October 2024. Ten RCTs involving 868 patients were included. Outcomes assessed included effectiveness rate, recurrence rate, pruritus scores, inflammatory cytokine levels, Dermatology Life Quality Index (DLQI), and adverse events. Data were analyzed using RevMan 5.4.1, with effect sizes expressed as risk ratios or mean differences.

RESULTS: Fire needling monotherapy showed no significant superiority over conventional treatment in effectiveness rates (p > 0.05). However, combined therapy demonstrated significantly higher effectiveness at the >90% threshold after 4 weeks (RR: 2.04, 95% CI: 1.61-2.59) and reduced recurrence rates within 6 months after 2-week treatment (RR: 0.36, 95% CI: 0.14-0.93). Combined therapy also improved DLQI scores (MD: -3.91, 95% CI: -6.15 to -1.67) and reduced pruritus (MD: -0.25, 95% CI: -0.43 to -0.07) and inflammatory markers (TNF-α, IL-4, IL-6, IL-8, IgE; p  0.05). Adverse events were mild.

CONCLUSION: Fire needling therapy combined with conventional treatment may enhance therapeutic outcomes for neurodermatitis, particularly in reducing pruritus, improving quality of life, and modulating inflammation. However, limitations include methodological flaws in included studies and regional publication bias. Higher-quality RCTs are needed to validate these findings and clarify long-term effectiveness.

SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024617150, identifier CRD42024617150.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты